MDREX has strengthened its Contract Sales Organization (CSO) capabilities with the appointment of Sung Dong (Sean) Min as the Commercial Director, a seasoned leader with extensive commercialization experience in the global medical device industry. This strategic expansion goes beyond regulatory approval and reimbursement support, enabling MDREX to deliver execution-focused services that drive real market entry and revenue generation for overseas medical device companies entering Korea.

The Korean market is widely recognized for its advanced healthcare system and complex regulatory and reimbursement environment. Successful market entry requires a well-coordinated approach across the entire value chain—from regulatory approval (MFDS), clinical evidence generation, and reimbursement listing (HIRA), to hospital adoption and KOL engagement. In this context, having a capable local partner is critical.

With extensive leadership experience at Teleflex (North Asia Lead), BD(Becton Dickinson), Philips, and Johnson & Johnson Medical, Sung Dong (Sean) Min is a seasoned expert in medical device commercialization. He specializes in driving market entry for innovative products across Asia, encompassing long-term strategic planning, clinical positioning, reimbursement strategies, and KOL network cultivation. His proven track record of bridging regulatory requirements with practical hospital adoption makes him a vital asset for any market expansion initiative.

Building on this strong commercialization expertise, MDREX provides integrated, end-to-end support for overseas medical device companies entering Korea. This includes regulatory strategy and technical documentation support, clinical data utilization strategies, reimbursement and pricing strategy, import pricing, go-to-market strategy including hospital sales and distribution, and KOL network development.

With the enhanced CSO capabilities, MDREX is now uniquely positioned to support clients not only in obtaining approvals, but also in ensuring that their products are successfully adopted in hospitals and generate sustainable revenue. This execution-driven approach will enable overseas companies to minimize risks and achieve faster, more effective market penetration in Korea. For more detailed information, please visit our CSO website (https://cso.mdrex.co.kr/).